BioSpace News Archive

Shares of Verastem closed out Monday trading on a positive note and continues to climb in the premarket following the greenlight for leukemia drug Copiktra, an inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma.

AstraZeneca and its MedImmune division released data on overall survival (OS) in its Phase III PACIFIC clinical trial of Imfinzi (durvalumab).

Swiss pharmaceutical giant Novartis plans to slash approximately 2,200 jobs in Switzerland over the next four years.

This morning, Genentech released results of its Phase III IMpower 133 trial that showed treatment with Tecentriq plus chemotherapy helped people with extensive-stage small cell lung cancer live significantly longer than with chemotherapy alone.

Going out of your way to overly ingratiate yourself with your boss (aka “kissing up”) may not be the most ‘attractive’ quality to display in the workplace, but there’s no denying that being proactive about getting your boss on your side can have some positive results … for the short term, anyway.

As the acquisition of Dublin-based Shire by Japan-based Takeda Pharmaceutical edges forward, yet another major Takeda shareholder has spoken out in opposition to the deal.

Clinical Evidence Shared at TCT and CIRSE Reaffirm IN.PACT(TM) Admiral(TM) Drug-Coated Balloon as a Primary Therapy to Treat Complex, Real-World Patient Populations

Biotechnology company Morphic Therapeutic has just publicized their completion of a successful $80 million Series B financing meant to support their two lead programs in developing modern oral integrin therapies, as well as further other clinic programs.

A commercially-available medical device developed by Medtronic is helping paralyzed patients walk again.The device, which stimulates the spinal cord through electrical pulses, has been successful in helping some individuals who lost the ability to walk through injuries to their spine, regain the ability to walk in a limited fashion.

Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalcoholic steatohepatitis, also known as NASH.